The long-term outcomes following the use of inactivated autograft in the treatment of primary malignant musculoskeletal tumor

Yang, Jielai; Zhu, Bin; Fu, Kai; Yang, Qingcheng

doi:10.1186/s13018-015-0324-3

Journal of Orthopaedic Surgery and Research

Table 1 Details of patients who underwent reconstruction with inactivated autograft treated with alcohol

From: The long-term outcomes following the use of inactivated autograft in the treatment of primary malignant musculoskeletal tumor

Case	Gender and age(Y)	Location	Stage^a	Histology	Length, cm	Resection	MSTSS score ,%	Outcomes	Follow-up (months)
1	M/12	DF	IIB	OSA	15	IA	81	Death	29
2	M/16	PT	IIB	OSA	18	IA	92	DF	61
3	F/21	PT	IIB	CHOS	21	IA	95	DF	70
4	M/12	DF	IIB	OSA	17	IA	81	DF	78
5	F/13	PT	IIB	OSA	23	IC	73	DF	69
6	F/17	PT	IIB	OSA	16	IA	85	DF	73
7	M/2O	PF	IIB	SSA	25	IA	69	Death	23
8	M/16	DF	IB	OSA	18	IC	67	DF	90
9	M/32	PT	IIB	CHOS	16	IA	98	DF	84
10	F/11	PH	IB	OSA	27	IA	87	DF	96
11	F/15	SH	IIB	0SA	21	IC	89	Death	40
12	M/19	DF	IIB	SSA	15	EA	72	Death	43
13	M/14	DF	IIB	EWS	18	IC	78	Death	48
14	M/23	PT	IIB	CHOS	19	IA	91	DF	72
15	M/17	PF	IIB	OSA	31	IA	76	DF	68
16	F/13	DF	IIB	OSA	22	EA	80	Death	55
17	F/19	PT	IB	IGTB	19	IC	77	DF	88
18	M/39	PT	IB	CHOS	17	IA	96	Death	56
19	M/26	DF	IIB	CHOS	22	IA	72	DF	60
20	M/21	PT	IIB	MCHOS	23	IA	94	DF	62
21	F/15	DF	IIB	OSA	28	IA	85	Death	36
22	F/14	PF	IB	IGTB	24	IA	70	Death	29
23	M/15	PT	IIB	OSA	16	IC	87	DF	70
24	M/26	DF	IIB	MCHOS	17	IA	85	Death	18
25	F/18	PT	IIB	OSA	19	IC	78	DF	79
26	M/2O	DF	IIB	FSA	18	IA	67	Death	28
27	F/13	DF	IIB	EWS	30	IA	54	Death	41
28	F/16	PT	IB	OSA	21	IA	86	Death	38
29	M/25	PT	IIB	CHOS	25	IA	74	DF	64
30	M/17	PH	IIB	OSA	17	EA	47	Death	28
31	F/12	DF	IB	OSA	19	IA	86	DF	65
32	M/15	PT	IIB	IGTB	23	IA	95	DF	96
33	M/19	DF	IIB	FSA	29	IA	82	Death	29
34	F/22	PT	IIB	MCHOS	22	IA	83	Death	38
35	F/13	DF	IB	OSA	25	IC	70	DF	80
36	M/18	PT	IIB	OSA	18	EA	93	Death	34
37	F/45	DF	IIB	CHOS	15	IA	85	DF	70
38	F/16	PT	IIB	0SA	19	IA	67	DF	66
39	M/19	DF	IIB	SSA	21	IA	94	Death	53
40	M/13	PT	IIB	MFCT	29	IA	73	Death	48
41	M/21	DF	IB	CHOS	18	IC	49	Death	36
42	M/14	PH	IIB	OSA	16	IA	85	Death	52
43	M/19	DF	IIB	OSA	14	IA	79	DF	78
44	M/2O	PT	IB	MCHOS	19	IA	70	Death	30
45	F/12	DF	IIB	OSA	21	IA	81	Death	42
46	F/17	PT	IIB	OSA	29	IA	58	Death	23
47	M/15	PT	IIB	OSA	31	IA	84	DF	88
48	M/21	DF	IB	MCHOS	17	IA	78	Death	55
49	F/16	PH	IIB	OSA	19	IC	59	Death	28
50	F/19	PT	IIB	SSA	21	IA	80	Death	34
51	F/11	DF	IIB	OSA	27	IA	71	Death	33
52	F/17	PT	IIB	OSA	22	IA	97	DF	82
53	M/38	PT	IB	CHOS	25	IA	71	Death	46
54	M/12	DF	IIB	OSA	17	IC	93	Death	58
55	M/15	PT	IIB	MFCT	19	IA	48	Death	19
56	F/11	DF	IIB	OSA	26	IA	75	DF	72
57	F/24	PT	IB	CHOS	19	IC	79	Death	46
58	M/13	PT	IIB	SSA	17	IA	83	Death	55

DF distal femur, PF proximal femur, PH proximal humerus, PT proximal tibia, SH shaft humerus, OSA osteosarcoma, CHOS chondrosarcoma, MCHOS mucus chondrosarcoma, FSA fibrosarcoma, EWS Ewing’s sarcoma, IGTB invasive giant cell tumor of bone, MFCT malignant fibrous cell tumors, SSA synovial sarcoma, EA extra-articular, IA intra-articular, IC intercalary, DF disease free
^aEnneking surgical stage

Back to article page

ISSN: 1749-799X

Contact us

Submission enquiries: journalsubmissions@springernature.com